Articles Tagged With: clopidogrel
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Long-Term Maintenance Therapy After Percutaneous Coronary Intervention
An extended six-year follow-up of the HOST-EXAM study revealed the consistent benefit of the primary endpoint of fewer major cardiovascular events and less bleeding with clopidogrel vs. low-dose aspirin monotherapy in post-percutaneous coronary intervention patients who were on dual antiplatelet therapy for one year.
-
The Limits of Shortened Antiplatelet Therapy in Acute Coronary Syndrome
One month of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy did not meet criteria for noninferiority vs.12 months of DAPT for a composite endpoint of ischemic and bleeding events.
-
Aspirin, Clopidogrel, or Both After Coronary Interventions?
A recent study of patients who had undergone a percutaneous coronary intervention and were transitioning from dual antiplatelet therapy to monotherapy showed clopidogrel was superior to aspirin for preventing further major adverse events, including bleeding. -
Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke
Ticagrelor is an antiplatelet agent that works by reversibly binding to P2Y12 adenosine diphosphate receptors on platelets, similar to the mechanism of action of clopidogrel. However, it is a direct-acting drug, and not a pro-drug, and does not need to be enzymatically converted to be active, like clopidogrel.
-
Ticagrelor in the Elderly: More Potent Platelet Inhibition Not Always Better
In a study of 14,000 elderly patients with acute myocardial infarction, treatment with ticagrelor was associated with higher risks of bleeding and all-cause death vs. clopidogrel.
-
Disability After Minor Stroke and TIA — Secondary Analysis of the POINT Trial
Although the data from this analysis suggest disability might be less with dual antiplatelet therapy, differences between the groups were small, did not show robust findings, and did not reach statistical significance in most of the analyses.
-
Antiplatelet Agents Add to Bleeding Risk, Do Not Add Benefit in TAVR Patients Already on Oral Anticoagulation
In a randomized trial of patients already on anticoagulation undergoing transcatheter aortic valve replacement, adding clopidogrel to oral anticoagulation increased the incidence of serious bleeding vs. oral anticoagulation alone, but did not improve cardiovascular outcomes.
-
Dual Antiplatelet Therapy Results in Increase in Serious Hemorrhages Following TIA or Minor Stroke
-
Dual Antiplatelet Therapy for Acute Ischemic Stroke and TIA